QURE – uniQure N.V.
Float Short %
21.12
Margin Of Safety %
Put/Call OI Ratio
0.19
EPS Next Q Diff
0.62
EPS Last/This Y
1.57
EPS This/Next Y
0.71
Price
25.09
Target Price
52.27
Analyst Recom
1.29
Performance Q
-58.14
Relative Volume
1.35
Beta
0.67
Ticker: QURE
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-26 | QURE | 24.82 | 0.24 | 0.13 | 151430 |
| 2025-12-29 | QURE | 24.61 | 0.24 | 0.22 | 152631 |
| 2025-12-30 | QURE | 23.8 | 0.24 | 0.49 | 152912 |
| 2025-12-31 | QURE | 23.95 | 0.24 | 0.11 | 153034 |
| 2026-01-02 | QURE | 23.39 | 0.24 | 0.53 | 153188 |
| 2026-01-05 | QURE | 22.59 | 0.25 | 0.52 | 153472 |
| 2026-01-06 | QURE | 22.29 | 0.25 | 0.06 | 154033 |
| 2026-01-07 | QURE | 23.08 | 0.25 | 0.30 | 155538 |
| 2026-01-08 | QURE | 23.16 | 0.24 | 0.55 | 156054 |
| 2026-01-09 | QURE | 25.29 | 0.24 | 0.07 | 156227 |
| 2026-01-12 | QURE | 23.03 | 0.23 | 0.25 | 172359 |
| 2026-01-13 | QURE | 21.47 | 0.23 | 0.55 | 175210 |
| 2026-01-14 | QURE | 22.39 | 0.23 | 0.36 | 176550 |
| 2026-01-15 | QURE | 22.1 | 0.22 | 0.19 | 178268 |
| 2026-01-16 | QURE | 22.87 | 0.21 | 0.28 | 192376 |
| 2026-01-20 | QURE | 22.52 | 0.18 | 0.75 | 120627 |
| 2026-01-21 | QURE | 21.74 | 0.19 | 0.13 | 122206 |
| 2026-01-22 | QURE | 22.75 | 0.19 | 0.16 | 123345 |
| 2026-01-23 | QURE | 25.12 | 0.19 | 0.09 | 124972 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-12-26 | QURE | 24.81 | 44.9 | 28.4 | -3.35 |
| 2025-12-29 | QURE | 24.57 | 44.9 | 27.2 | -3.35 |
| 2025-12-30 | QURE | 23.80 | 44.9 | 32.3 | -3.35 |
| 2025-12-31 | QURE | 23.94 | 44.9 | 23.4 | -3.35 |
| 2026-01-02 | QURE | 23.44 | 44.9 | 29.9 | -3.35 |
| 2026-01-05 | QURE | 22.60 | 44.9 | 33.1 | -3.35 |
| 2026-01-06 | QURE | 22.30 | 44.9 | 28.4 | -3.35 |
| 2026-01-07 | QURE | 23.06 | 44.9 | 16.6 | -3.35 |
| 2026-01-08 | QURE | 23.17 | 44.9 | 24.1 | -3.35 |
| 2026-01-09 | QURE | 25.31 | 44.9 | 2.2 | -3.35 |
| 2026-01-12 | QURE | 23.04 | 44.9 | 45.5 | -3.35 |
| 2026-01-13 | QURE | 21.50 | 44.9 | 41.3 | -3.35 |
| 2026-01-14 | QURE | 22.32 | 44.9 | 15.1 | -3.35 |
| 2026-01-15 | QURE | 22.00 | 44.9 | 28.6 | -3.35 |
| 2026-01-16 | QURE | 22.90 | 44.9 | 14.3 | -3.35 |
| 2026-01-20 | QURE | 22.44 | 44.9 | 29.3 | -3.35 |
| 2026-01-21 | QURE | 21.74 | 44.9 | 32.4 | -3.35 |
| 2026-01-22 | QURE | 22.71 | 44.9 | 13.6 | -3.35 |
| 2026-01-23 | QURE | 25.09 | 45.2 | -0.5 | -3.35 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-12-26 | QURE | -6.13 | -6.68 | 15.79 |
| 2025-12-29 | QURE | -6.13 | -6.63 | 15.79 |
| 2025-12-30 | QURE | -6.13 | -6.63 | 15.79 |
| 2025-12-31 | QURE | -6.13 | -6.63 | 15.79 |
| 2026-01-02 | QURE | -6.11 | -6.63 | 15.79 |
| 2026-01-05 | QURE | -6.11 | -6.62 | 15.79 |
| 2026-01-06 | QURE | -6.11 | -6.62 | 15.79 |
| 2026-01-07 | QURE | -6.11 | -6.62 | 15.79 |
| 2026-01-08 | QURE | -6.11 | -6.62 | 15.79 |
| 2026-01-09 | QURE | -6.11 | -6.62 | 15.79 |
| 2026-01-12 | QURE | -6.22 | 2.66 | 15.79 |
| 2026-01-13 | QURE | -6.22 | 2.66 | 21.13 |
| 2026-01-14 | QURE | -6.69 | 2.66 | 21.13 |
| 2026-01-15 | QURE | -6.69 | 2.66 | 21.13 |
| 2026-01-16 | QURE | -6.69 | 2.66 | 21.12 |
| 2026-01-20 | QURE | -6.71 | 3.32 | 21.12 |
| 2026-01-21 | QURE | -6.72 | 3.32 | 21.12 |
| 2026-01-22 | QURE | -6.72 | 3.32 | 21.12 |
| 2026-01-23 | QURE | -6.72 | 3.32 | 21.12 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.38
Avg. EPS Est. Current Quarter
-0.8
Avg. EPS Est. Next Quarter
-0.77
Insider Transactions
-6.72
Institutional Transactions
3.32
Beta
0.67
Average Sales Estimate Current Quarter
4
Average Sales Estimate Next Quarter
5
Fair Value
Quality Score
40
Growth Score
32
Sentiment Score
51
Actual DrawDown %
64.9
Max Drawdown 5-Year %
-90.5
Target Price
52.27
P/E
Forward P/E
PEG
P/S
98.1
P/B
6.82
P/Free Cash Flow
EPS
-4.39
Average EPS Est. Cur. Y
-3.35
EPS Next Y. (Est.)
-2.64
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-1492.9
Relative Volume
1.35
Return on Equity vs Sector %
-130.1
Return on Equity vs Industry %
-114.1
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.59
EBIT Estimation
-0.5
uniQure N.V.Sector: Healthcare
Industry: Biotechnology
Employees: 209
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
stock quote shares QURE – uniQure N.V. Stock Price stock today
news today QURE – uniQure N.V. stock forecast ,stock prediction 2023 2024 2025
marketwatch QURE – uniQure N.V. yahoo finance google finance
stock history QURE – uniQure N.V. invest stock market
stock prices QURE premarket after hours
ticker QURE fair value insiders trading